Treatment Outcomes in Stage I Lung Cancer

Slides:

Advertisements

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Advertisements

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Stephen R. Broderick, MD, MPHS

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus Yang Zhao, MD, ZhiJun Dai,

Michael Y. Chang, MD, MPH, Steven J. Mentzer, MD, Yolonda L

Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F

Evaluation of the Reliability of Clinical Staging of T2 N0 Esophageal Cancer: A Review of The Society of Thoracic Surgeons Database Traves D. Crabtree,

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

Survival after Sublobar Resection for Early-Stage Lung Cancer: Methodological Obstacles in Comparing the Efficacy to Lobectomy Emanuela Taioli, MD, PhD,

Endoscopic Ultrasound for Early Stage Esophageal Adenocarcinoma: Implications for Staging and Survival Traves D. Crabtree, MD, Wael N. Yacoub, MD, Varun.

ALK FISH and IHC: You Cannot Have One without the Other

Does the method of radiologic surveillance affect survival after resection of stage I non– small cell lung cancer? Traves D. Crabtree, MD, Varun Puri,

Paul J. Scheel, BS, Traves D. Crabtree, MD, Jennifer M

Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC

Matthew J. Boyer, MD, PhD, Christina D. Williams, PhD, MPH, David H

Clinical T2N0 Esophageal Cancer: Identifying Pretreatment Characteristics Associated With Pathologic Upstaging and the Potential Role for Induction Therapy

Electronic Updates for JTO Readers

Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer Masatsugu Hamaji,

Joshua E. Rosen, BASc, Michelle C

National Patterns of Care and Outcomes After Combined Modality Therapy for Stage IIIA Non–Small-Cell Lung Cancer Aalok P. Patel, BS, Traves D. Crabtree,

A single-center experience of 1500 lung transplant patients

Varun Puri, MD, Andrew Tran, MS, Jennifer M. Bell, BS, Traves D

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Benefits of resection for metachronous lung cancer

Utility of mediastinoscopy in clinical stage I lung cancers at risk for occult mediastinal nodal metastases Felix G. Fernandez, MD, Benjamin D. Kozower,

A Combined Prognostic Serum Interleukin-8 and Interleukin-6 Classifier for Stage 1 Lung Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening.

Adjuvant Chemotherapy Is Associated With Improved Survival in Locally Invasive Node Negative Non-Small Cell Lung Cancer Usman Ahmad, MD, Traves D. Crabtree,

Defining the Ideal Time Interval Between Planned Induction Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer Pamela Samson, MD, MPHS, Traves.

The Role of Surgical Resection in Stage IIIA Non-Small Cell Lung Cancer: A Decision and Cost-Effectiveness Analysis Pamela Samson, MD, Aalok Patel, BS,

Tara R. Semenkovich, MD, MPHS, Christine Frederiksen, MS, Jessica L

Quality Measures in Clinical Stage I Non-Small Cell Lung Cancer: Improved Performance Is Associated With Improved Survival Pamela Samson, MD, MPHS, Traves.

The National Surgical Quality Improvement Program risk calculator does not adequately stratify risk for patients with clinical stage I non–small cell.

Clinical Characteristics and Outcomes for Patients With Thymic Carcinoma: Evaluation of Masaoka Staging Anya M. Litvak, MD, Kaitlin Woo, MS, Sara Hayes,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Increasing Rates of No Treatment in Advanced-Stage Non–Small Cell Lung Cancer Patients: A Propensity-Matched Analysis Elizabeth A. David, MD, Megan E.

Ellen Kim, MD, MPH, Siran Koroukian, PhD, Charles R. Thomas, MD

A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non–small cell lung cancer Christopher.

Maria Q. Baggstrom, MD, Saiama N. Waqar, MD, Ananth K

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Onkar V. Khullar, MD, Yuan Liu, PhD, Theresa Gillespie, PhD, Kristin A

Yinin Hu, MD, Varun Puri, MD, Traves D

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Do we need a bibliometrician to know which way the wind is blowing?

Mitotic Inhibitors Journal of Thoracic Oncology

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Stephen R. Broderick, MD, MPHS

Extent of Lymphadenectomy Is Associated With Improved Overall Survival After Esophagectomy With or Without Induction Therapy Pamela Samson, MD, MPHS,

Mirror Mirror on the Wall, Who Is the Fairest of Them All

Mara B. Antonoff, MD, Varun Puri, MD, Bryan F

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Jason M. Gauthier, MD, Ruben G. Nava, MD, Daniel Kreisel, MD, PhD

Daniel Kreisel, MD, PhD, Alexander S

Role of Postoperative Radiotherapy in Nonlocalized Thymoma

Office-Based Spirometry: A New Model of Care in Preoperative Assessment for Low- Risk Lung Resections Jessica L. Hudson, MD, MPHS, Jennifer M. Bell, BSN,

Conditional Survival of Malignant Thymoma Using National Population-Based Surveillance, Epidemiology, and End Results (SEER) Registry (1973–2011) Ellen.

Bolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base Susan E. Combs, MA, Jacquelyn.

MTP19-01: T4 N0/N1 nonsmall cell lung cancer can be cured as a first line treatment with an expected five year survival rate as high as 43% provided a.

Adhering to Quality Measures in Esophagectomy Is Associated With Improved Survival in All Stages of Esophageal Cancer Pamela Samson, MD, MPHS, Varun.

Stephen R. Broderick, MD, MPHS, Aalok P. Patel, BS, BA, Traves D

Outcome of Multimodality Treatment for 188 Cases of Type B3 Thymoma

Patterns of care in hilar node-positive (N1) non–small cell lung cancer: A missed treatment opportunity? Matthew J. Bott, MD, Aalok P. Patel, BS, Vivek.

Effects of Delayed Surgical Resection on Short-Term and Long-Term Outcomes in Clinical Stage I Non-Small Cell Lung Cancer Pamela Samson, MD, Aalok Patel,

Surveillance and the second primary lung cancer: Enhancing our understanding beyond Martini and Melamed Melanie P. Subramanian, MD, Varun Puri, MD, MSCI

Lobectomy versus stereotactic body radiotherapy for stage I non–small cell lung cancer: Post hoc analysis dressed up as level-1 evidence? Bryan F. Meyers,

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

Varun Puri, MD, Yinin Hu, MS, Tracey Guthrie, RN, Traves D

Liseth L. van den Berg, MD, Theo J. Klinkenberg, MD, Harry J. M

Treatment of Malignant Pleural Effusion: A Cost-Effectiveness Analysis

Presentation transcript:

Treatment Outcomes in Stage I Lung Cancer Varun Puri, MD, MSCI, Traves D. Crabtree, MD, Jennifer M. Bell, BSN, Stephen R Broderick, MD, Daniel Morgensztern, MD, Graham A. Colditz, MD, DrPH, Daniel Kreisel, MD, PhD, A. Sasha Krupnick, MD, G. Alexander Patterson, MD, Bryan F. Meyers, MD, MPH, Aalok Patel, BS, Clifford G. Robinson, MD Journal of Thoracic Oncology Volume 10, Issue 12, Pages 1776-1784 (December 2015) DOI: 10.1097/JTO.0000000000000680 Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Consort diagram showing schema of study subject selection and analysis. Journal of Thoracic Oncology 2015 10, 1776-1784DOI: (10.1097/JTO.0000000000000680) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 A, Kaplan–Meier survival of patients undergoing surgery versus SBRT. This is an unmatched comparison (A) and propensity score matched comparison (B). Kaplan–Meier survival of patients undergoing sublobar resection (wedge or segmentectomy) versus SBRT. This is an unmatched comparison (C) and propensity score matched comparison (D). Journal of Thoracic Oncology 2015 10, 1776-1784DOI: (10.1097/JTO.0000000000000680) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions